Related Experiment Videos
[Phase I study of FK 435]
1Dept. of Surgery, School of Med. Keio Univ.
Gan No Rinsho. Japan Journal of Cancer Clinics
|July 1, 1990
Summary
FK 435, a novel antiestrogen, demonstrated good tolerability in a phase I study involving 30 advanced breast cancer patients. Adverse reactions were mild, with most of the drug excreted in urine.
Area of Science:
- Oncology
- Pharmacology
- Endocrinology
Background:
- Advanced breast cancer remains a significant clinical challenge.
- Antiestrogens are crucial in managing hormone-sensitive breast cancers.
- Novel antiestrogen therapies are needed to improve treatment outcomes.
Purpose of the Study:
- To evaluate the safety and tolerability of FK 435, a new antiestrogen.
- To determine the pharmacokinetic profile of FK 435 in patients with advanced breast cancer.
- To identify potential adverse reactions associated with FK 435 administration.
Main Methods:
- Phase I clinical trial design.
- Inclusion of 30 patients with advanced breast cancer.
- Administration of single and repeated doses of FK 435.
- Monitoring of adverse events and pharmacokinetic parameters (Tmax, T1/2).
Main Results:
- FK 435 was generally well tolerated across dose levels.
- Reported adverse reactions were predominantly mild to moderate.
- Pharmacokinetic analysis indicated a Tmax of 3-5 hours and a T1/2 of approximately 25 hours.
- Urinary excretion of FK 435, primarily as a glucuronide metabolite, was observed.
Conclusions:
- FK 435 exhibits a favorable safety profile in patients with advanced breast cancer.
- The pharmacokinetic properties suggest potential for sustained therapeutic levels.
- FK 435 warrants further investigation in clinical trials for breast cancer treatment.